Neura Therapeutik, LLC (Neura) is a privately held pain specialty company focused on the commercialization of innovative analgesics that address unmet needs in the marketplace. Extended capabilities allow Neura to capitalize on near-term product opportunities outside of the analgesic market that will facilitate the advancement of Neura’s analgesic portfolio.
FLEMINGTON, N.J., April 18, 2013 /PRNewswire/ — Neura Therapeutik announced today that they will be accelerating the development of their abuse-deterrent brand and generic extended-release opioids. This is in response to the Food and Drug Administration's recent announcement that they will not approve any generic to the original version of OxyContin® extended release oxycodone. The currently […]
Abuse-Deterrent Opioid from Neura Therapeutik Complies with FDA Draft Guidance
PRINCETON, N.J., Jan. 15, 2013 /PRNewswire/ — Neura Therapeutik announced today the securing of terms on NL-001, an abuse-deterrent, long-acting opioid analgesic and that studies conducted on NL-001 comply with recent FDA draft guidance. Issued last week, this guidance is intended to assist pharmaceutical companies who wish to develop abuse deterrent opioid formulations. Prescription opioids are […]
Neura Therapeutik Forms Business Units to Pursue Analgesic Market Opportunities
PRINCETON, N.J., July 31, 2012 — Neura Therapeutik, LLC, a privately held specialty pharmaceutical company, announced today the formation of two strategic business units to capitalize on current and future opportunities in the analgesic market. The formation of Neura Group, LLC and Neura Labs, LLC structures the company to efficiently pursue commercial services, in-licensing, and […]
